1. Scrip
  2. >>Business

Arcus And Gilead Keep TIGIT Dream Alive Despite Trial Shortcomings

Still In The Game After Mixed Phase II Results

 
• By Andrew McConaghie

Arcus and Gilead’s latest Phase II readout has produced mixed signals, but some analysts are reassured about the potential of domvanalimab and the wider TIGIT field.

Arcus Biosciences
• Source: Shutterstock

Shares in Arcus and Gilead have been hit by a negative market reaction to their latest Phase II data update on domvanalimab, a TIGIT cancer immunotherapy candidate being studied in first-line non-small cell lung cancer (NSCLC).

Arcus was hit hard when the ARC-7 study results were unveiled on 19 December, and after the presentation at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By Mandy Jackson

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.